433 related articles for article (PubMed ID: 22228328)
1. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
2. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
3. Chordoma of the mobile spine: fifty years of experience.
Boriani S; Bandiera S; Biagini R; Bacchini P; Boriani L; Cappuccio M; Chevalley F; Gasbarrini A; Picci P; Weinstein JN
Spine (Phila Pa 1976); 2006 Feb; 31(4):493-503. PubMed ID: 16481964
[TBL] [Abstract][Full Text] [Related]
4. En bloc excisions of chordomas in the cervical spine: review of five consecutive cases with more than 4-year follow-up.
Hsieh PC; Gallia GL; Sciubba DM; Bydon A; Marco RA; Rhines L; Wolinsky JP; Gokaslan ZL
Spine (Phila Pa 1976); 2011 Nov; 36(24):E1581-7. PubMed ID: 22048652
[TBL] [Abstract][Full Text] [Related]
5. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients.
Hsieh PC; Xu R; Sciubba DM; McGirt MJ; Nelson C; Witham TF; Wolinksy JP; Gokaslan ZL
Spine (Phila Pa 1976); 2009 Sep; 34(20):2233-9. PubMed ID: 19752710
[TBL] [Abstract][Full Text] [Related]
7. Challenges of local recurrence and cure in low grade malignant tumors of the spine.
Boriani S; Saravanja D; Yamada Y; Varga PP; Biagini R; Fisher CG
Spine (Phila Pa 1976); 2009 Oct; 34(22 Suppl):S48-57. PubMed ID: 19829277
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic factors for survival in patients with primary spinal chordoma using the SEER Registry from 1973 to 2014.
Pan Y; Lu L; Chen J; Zhong Y; Dai Z
J Orthop Surg Res; 2018 Apr; 13(1):76. PubMed ID: 29625617
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
11. Outcomes following attempted en bloc resection of cervical chordomas in the C-1 and C-2 region versus the subaxial region: a multiinstitutional experience.
Molina CA; Ames CP; Chou D; Rhines LD; Hsieh PC; Zadnik PL; Wolinsky JP; Gokaslan ZL; Sciubba DM
J Neurosurg Spine; 2014 Sep; 21(3):348-56. PubMed ID: 24926926
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
[TBL] [Abstract][Full Text] [Related]
14. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors.
Rotondo RL; Folkert W; Liebsch NJ; Chen YL; Pedlow FX; Schwab JH; Rosenberg AE; Nielsen GP; Szymonifka J; Ferreira AE; Hornicek FJ; DeLaney TF
J Neurosurg Spine; 2015 Dec; 23(6):788-97. PubMed ID: 26340383
[TBL] [Abstract][Full Text] [Related]
15. Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database.
Gokaslan ZL; Zadnik PL; Sciubba DM; Germscheid N; Goodwin CR; Wolinsky JP; Bettegowda C; Groves ML; Luzzati A; Rhines LD; Fisher CG; Varga PP; Dekutoski MB; Clarke MJ; Fehlings MG; Quraishi NA; Chou D; Reynolds JJ; Williams RP; Kawahara N; Boriani S
J Neurosurg Spine; 2016 Apr; 24(4):644-51. PubMed ID: 26682601
[TBL] [Abstract][Full Text] [Related]
16. Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure.
Noël G; Habrand JL; Jauffret E; de Crevoisier R; Dederke S; Mammar H; Haie-Méder C; Pontvert D; Hasboun D; Ferrand R; Boisserie G; Beaudré A; Gaboriaud G; Guedea F; Petriz L; Mazeron JJ
Strahlenther Onkol; 2003 Apr; 179(4):241-8. PubMed ID: 12707713
[TBL] [Abstract][Full Text] [Related]
17. [Sacral chordoma: retrospective review of 11 surgically treated cases].
Jeanrot C; Vinh TS; Anract P; De Pinieux G; Ouaknine M; Forest M; Tomeno B
Rev Chir Orthop Reparatrice Appar Mot; 2000 Nov; 86(7):684-93. PubMed ID: 11104990
[TBL] [Abstract][Full Text] [Related]
18. Sacrectomy and adjuvant radiotherapy for the treatment of sacral chordomas: a single-center experience over 27 years.
Dhawale AA; Gjolaj JP; Holmes L; Sands LR; Temple HT; Eismont FJ
Spine (Phila Pa 1976); 2014 Mar; 39(5):E353-9. PubMed ID: 24365895
[TBL] [Abstract][Full Text] [Related]
19. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
20. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
